HK1201741A1 - Method of prevention of neurological diseases - Google Patents
Method of prevention of neurological diseasesInfo
- Publication number
- HK1201741A1 HK1201741A1 HK15102320.0A HK15102320A HK1201741A1 HK 1201741 A1 HK1201741 A1 HK 1201741A1 HK 15102320 A HK15102320 A HK 15102320A HK 1201741 A1 HK1201741 A1 HK 1201741A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prevention
- neurological diseases
- neurological
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655742P | 2012-06-05 | 2012-06-05 | |
| PCT/US2013/043927 WO2013184591A1 (en) | 2012-06-05 | 2013-06-03 | Method of prevention of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201741A1 true HK1201741A1 (en) | 2015-09-11 |
Family
ID=49712532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102320.0A HK1201741A1 (en) | 2012-06-05 | 2015-03-06 | Method of prevention of neurological diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10258632B2 (es) |
| EP (1) | EP2841060A4 (es) |
| JP (1) | JP2015518887A (es) |
| KR (1) | KR20150023292A (es) |
| CN (1) | CN104379136A (es) |
| AU (1) | AU2013271841B2 (es) |
| CA (1) | CA2875330A1 (es) |
| HK (1) | HK1201741A1 (es) |
| IL (1) | IL235736B (es) |
| MX (1) | MX2014014993A (es) |
| RU (1) | RU2014153894A (es) |
| SG (1) | SG11201407412QA (es) |
| WO (1) | WO2013184591A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3055548B1 (fr) | 2016-09-05 | 2018-09-28 | Metabrain Research | Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire |
| CN106265685A (zh) * | 2016-09-18 | 2017-01-04 | 南通大学 | 没药甾酮z在制备抗抑郁症药物中的应用 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| EP3659593A1 (en) * | 2018-11-30 | 2020-06-03 | Forschungszentrum Jülich GmbH/ Abteilung RP-PT | Trmt2a inhibitors for use in the treatment of polyglutamine diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6896901B2 (en) * | 2000-12-22 | 2005-05-24 | Council Of Scientific & Industrial Research | Method of treating a cognitive memory dysfunction using Gugulipid |
| KR20100056569A (ko) * | 2002-01-28 | 2010-05-27 | 교와 핫꼬 기린 가부시키가이샤 | 운동성 질환에 걸린 환자의 치료 방법 |
| US20090226536A1 (en) * | 2004-09-02 | 2009-09-10 | Arenas Ernesto A | Methods and materials relating to enhanced production of dopamine neurons |
| US20090291134A1 (en) * | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| WO2010088400A1 (en) * | 2009-01-28 | 2010-08-05 | Catholic Healthcare West | Methods of diagnosing and treating neurodegenerative diseases |
-
2013
- 2013-06-03 SG SG11201407412QA patent/SG11201407412QA/en unknown
- 2013-06-03 WO PCT/US2013/043927 patent/WO2013184591A1/en active Application Filing
- 2013-06-03 EP EP13800837.0A patent/EP2841060A4/en not_active Withdrawn
- 2013-06-03 RU RU2014153894A patent/RU2014153894A/ru not_active Application Discontinuation
- 2013-06-03 CA CA2875330A patent/CA2875330A1/en not_active Abandoned
- 2013-06-03 CN CN201380026036.0A patent/CN104379136A/zh active Pending
- 2013-06-03 AU AU2013271841A patent/AU2013271841B2/en active Active
- 2013-06-03 KR KR20147033073A patent/KR20150023292A/ko not_active Application Discontinuation
- 2013-06-03 JP JP2015516096A patent/JP2015518887A/ja active Pending
- 2013-06-03 US US14/397,981 patent/US10258632B2/en active Active
- 2013-06-03 MX MX2014014993A patent/MX2014014993A/es unknown
-
2014
- 2014-11-17 IL IL235736A patent/IL235736B/en not_active IP Right Cessation
-
2015
- 2015-03-06 HK HK15102320.0A patent/HK1201741A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150023292A (ko) | 2015-03-05 |
| IL235736A0 (en) | 2015-01-29 |
| US10258632B2 (en) | 2019-04-16 |
| US20150094289A1 (en) | 2015-04-02 |
| EP2841060A4 (en) | 2016-02-24 |
| AU2013271841B2 (en) | 2018-03-08 |
| CN104379136A (zh) | 2015-02-25 |
| RU2014153894A (ru) | 2016-08-10 |
| EP2841060A1 (en) | 2015-03-04 |
| MX2014014993A (es) | 2015-06-17 |
| SG11201407412QA (en) | 2014-12-30 |
| IL235736B (en) | 2020-06-30 |
| AU2013271841A1 (en) | 2014-11-27 |
| CA2875330A1 (en) | 2013-12-12 |
| JP2015518887A (ja) | 2015-07-06 |
| WO2013184591A1 (en) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1209793A1 (en) | Methods of detecting diseases or conditions | |
| EP2882429A4 (en) | METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES | |
| HK1199261A1 (en) | Methods for treatment of diseases | |
| HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
| IL234813A0 (en) | Methods for increasing the efficacy of cd37-based therapy | |
| EP2906295A4 (en) | METHODS OF TREATING OCULAR DISEASES | |
| HUE041814T2 (hu) | Eljárás izoidid elõállítására | |
| HK1216504A1 (zh) | 疾病的治療方法 | |
| IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
| GB201509165D0 (en) | Tampon method of manufacture | |
| EP2866757A4 (en) | BUFFER MANUFACTURING METHOD | |
| GB201220155D0 (en) | Method of manufacture | |
| IL238592A0 (en) | Methods for treating liver diseases | |
| HK1201741A1 (en) | Method of prevention of neurological diseases | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| GB201215942D0 (en) | Method of treatent | |
| EP2911662A4 (en) | METHOD OF TREATING A DISEASE | |
| GB201221032D0 (en) | Method of treatment | |
| GB201207894D0 (en) | Method of treatment | |
| GB201221118D0 (en) | Methods of treatment | |
| GB201216748D0 (en) | Methods of treatment | |
| GB201216740D0 (en) | Methods of treatment | |
| GB201206325D0 (en) | Methods of treatment | |
| GB201206330D0 (en) | Methods of treatment | |
| GB201206326D0 (en) | Methods of treatment |